Summit Therapeutics PLC (SMMT) Receives $28.33 Consensus PT from Analysts
Summit Therapeutics PLC (NASDAQ:SMMT) has earned a consensus recommendation of “Buy” from the eight analysts that are presently covering the company. One equities research analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $28.33.
SMMT has been the topic of several research analyst reports. Zacks Investment Research upgraded shares of Summit Therapeutics PLC from a “sell” rating to a “hold” rating in a research report on Wednesday, August 3rd. Canaccord Genuity set a $28.00 price target on Summit Therapeutics PLC and gave the stock a “buy” rating in a research note on Wednesday, October 5th. Royal Bank Of Canada lifted their price target on Summit Therapeutics PLC from $26.00 to $29.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 16th. RBC Capital Markets lifted their price target on Summit Therapeutics PLC from $26.00 to $29.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 16th. Finally, Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and set a $28.00 price target on shares of Summit Therapeutics PLC in a research note on Wednesday, October 5th.
Shares of Summit Therapeutics PLC (NASDAQ:SMMT) opened at 10.49 on Monday. Summit Therapeutics PLC has a 12-month low of $4.26 and a 12-month high of $19.75. The company has a 50 day moving average of $11.30 and a 200-day moving average of $8.69. The company’s market cap is $128.96 million.
ILLEGAL ACTIVITY NOTICE: This piece was originally published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this piece on another publication, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2016/12/01/summit-therapeutics-plc-smmt-receives-28-33-consensus-pt-from-analysts.html.
An institutional investor recently raised its position in Summit Therapeutics PLC stock. AXA boosted its stake in shares of Summit Therapeutics PLC (NASDAQ:SMMT) by 1.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 382,705 shares of the company’s stock after buying an additional 5,500 shares during the period. AXA owned about 3.12% of Summit Therapeutics PLC worth $2,989,000 at the end of the most recent quarter. 23.37% of the stock is currently owned by institutional investors.
Summit Therapeutics PLC Company Profile
Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).
Receive News & Stock Ratings for Summit Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics PLC and related stocks with our FREE daily email newsletter.